Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects.In Vivo: Vanucizumab (20 mg/kg; i.p.; once weekly; for 6 weeks) shows tumor growth inhibition and induces tumor stasis[2].